Neuroplasticity Treatment Method with Neurostimulation and Dopamine Agonist for Depression

USPTO published a patent application disclosing a method for modulating neuroplasticity using targeted energy-based neurostimulation (preferably transcranial magnetic stimulation) administered in combination with a dopamine receptor agonist and one or more neuroplasticity-enhancing drugs, with the treatment repeated within a single day. The preferred embodiment addresses depression treatment. The invention covers the specific combination protocol and timing of drug administration relative to neurostimulation sessions.

For pharmaceutical and medical device companies, this patent application represents potential prior art that could affect freedom-to-operate for competing neurostimulation or dopamine agonist combination therapies. Researchers and developers working in neuromodulation, psychiatric treatments, or neuroplasticity enhancement should monitor this application's prosecution and evaluate whether their technologies fall within the scope of the disclosed claims. Clinical investigators exploring combination neuromodulation approaches may find licensing opportunities upon patent grant.